Sign up to save your podcasts
Or
Share TROP2 ADCs for Metastatic NSCLC: Setting the Stage for Future Use
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
TROP2 ADCs for Metastatic NSCLC: Setting the Stage for Future Use
CME credits: 0.50
Valid until: 15-11-2023
Claim your CME credit at https://reachmd.com/programs/cme/trop2-adcs-for-metastatic-nsclc-setting-the-stage-for-future-use/14416/
Antibody-drug conjugates (ADCs) have promising clinical data in the treatment of advanced non-small cell lung cancer. Listen in as Drs. Benjamin Levy, Rebecca Heist, and Peter Illei discuss current data on TROP2 ADCs and what this means for our patients.
=
View all episodes
By ReachMD
4.3
33 ratings
CME credits: 0.50
Valid until: 15-11-2023
Claim your CME credit at https://reachmd.com/programs/cme/trop2-adcs-for-metastatic-nsclc-setting-the-stage-for-future-use/14416/
Antibody-drug conjugates (ADCs) have promising clinical data in the treatment of advanced non-small cell lung cancer. Listen in as Drs. Benjamin Levy, Rebecca Heist, and Peter Illei discuss current data on TROP2 ADCs and what this means for our patients.
=